Tosolini Matteo, Jouneau Alice
INRA, UMR1198 Biologie du Développement et Reproduction, F-78350, Jouy-en-Josas, France.
Methods Mol Biol. 2016;1341:209-16. doi: 10.1007/7651_2015_208.
Mouse embryonic stem cells (ESCs) derive from the inner cell mass (ICM) of a blastocyst at E3.5 while mouse epiblast stem cells (EpiSCs) derive from the late epiblast of a post-implantation embryo at E5.5-E7.5. Both cells are able to differentiate into derivatives of the three germs layers but only ESCs are able to produce chimeras when they are introduced into a blastocyst. To support the naive state of pluripotency, ESC culture requires Leukemia inhibitory factor (Lif) and either serum or inhibitors of Erk and Gsk3 pathways (2i) while the primed pluripotency of EpiSCs is maintained using Activin A and Fibroblast Growth Factor 2 (FGF2). It is possible to obtain EpiSCs in vitro starting from ESCs but also to induce ESCs starting from EpiSCs even if this second process is very difficult and inefficient. In this protocol we describe how we perform the process of conversion from ESCs to EpiSCs.
小鼠胚胎干细胞(ESCs)来源于E3.5期囊胚的内细胞团(ICM),而小鼠上胚层干细胞(EpiSCs)来源于E5.5 - E7.5期植入后胚胎的晚期上胚层。这两种细胞都能够分化为三个胚层的衍生物,但只有ESCs在被引入囊胚时能够产生嵌合体。为了维持多能性的原始状态,ESCs培养需要白血病抑制因子(Lif)以及血清或Erk和Gsk3信号通路抑制剂(2i),而使用激活素A和成纤维细胞生长因子2(FGF2)来维持EpiSCs的始发态多能性。从ESCs开始在体外获得EpiSCs是可能的,从EpiSCs开始诱导ESCs也是可能的,尽管第二个过程非常困难且效率低下。在本方案中,我们描述了如何进行从ESCs到EpiSCs的转化过程。